The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has selected Thomas Cueni as its new director general.
Cueni takes on responsibility for representing the interests of the research-based pharma industry at a global level, working with organisations and governments to promote the value of pharmaceutical innovation and improve access to treatments.
He brings considerable experience as secretary general of Interpharma, the Basel-based association representing Swiss pharma firms, during which time he had been closely associated with IFPMA as a member of its council.
Cueni also brings industry expertise from the European Federation of Pharmaceutical Industries and Associations (EFPIA), where he served in a policy-shaping and advocacy capacity.
Ian Read, IFPMA’s president and chief executive and chairman of Pfizer, said: “Thomas has extensive experience in the research-based biopharmaceutical industry and a deep understanding of what is needed to support the continued discovery and development of important life-saving and life-enhancing medicines and vaccines.
“I look forward to working closely with Thomas in advocating for sustainable health policies that foster innovation and ensure patient access to these important advances.”